Table 3.
Progression free survival (PFS) and overall survival (OS) according to baseline levels of serum tumour markers
| CEA | p-value(Log rank test) | ||
| ≤ 3 µg/l (n = 26) | > 3 µg/l (n = 62) | ||
| Median PFS (95% CI) | 10.27 months (7.29-17.83) | 10.24 months (8.57-13.06) | 0.5239 |
| 3-month PFS (95% CI) | 84.44% (70.52-98.37) | 92.21% (85.54-98.87) | |
| 6-month PFS (95% CI) | 76.47% (60.17-92.76) | 75.66% (64.98-86.34) | |
| 12-month PFS (95% CI) | 45.26% (25.86-64.65) | 44.50% (31.97-57.02) | |
| 18-month PFS (95% CI) | 31.24% (13.03-49.45) | 22.07% (11.51-32.63) | |
| Median OS (95% CI) | 36.62 months (17.91-52.24) | 34.32 months (26.23-42.92) | 0.9698 |
| 12-month OS (95% CI) | 82.25% (67.47-97.03) | 89.51% (81.77-97.24) | |
| 24-month OS (95% CI) | 63.32% (44.24-82.41) | 66.98% (54.60-79.36) | |
| 36-month OS (95% CI) | 51.18% (27.83-74.54) | 46.26% (30.93-61.59) | |
| CA 19-9 | p-value(Log rank test) | ||
| ≤ 28 µg/l (n = 60) | > 28 µg/l (n = 27) | ||
| Median PFS (95% CI) | 12.00 months (9.25-17.52) | 8.97 months (5.66-12.67) | 0.0232 |
| 3-month PFS (95% CI) | 95.17% (89.75-100.58) | 80.20% (65.19-95.21) | |
| 6-month PFS (95% CI) | 81.52% (71.70-91.34) | 65.95% (48.09-83.82) | |
| 12-month PFS (95% CI) | 49.96% (37.07-62.85) | 34.49% (16.58-52.41) | |
| 18-month PFS (95% CI) | 34.20% (21.84-46.55) | 7.06% (n.a.) | |
| Median OS (95% CI) | 41.82 months (34.42-51.61) | 19.19 months (14.00-27.24) | 0.0012 |
| 12-month OS (95% CI) | 94.22% (88.27-100.18) | 71.75% (54.48-89.03) | |
| 24-month OS (95% CI) | 74.58% (63.21-85.95) | 42.32% (21.75-62.90) | |
| 36-month OS (95% CI) | 62.36% (47.84-76.89) | < 14.42% (n.a.) | |
| TPS | p-value(Log rank test) | ||
| ≤ 90 µg/l (n = 22) | > 90 µg/l (n = 53) | ||
| Median PFS (95% CI) | 12.71 months (9.80-17.74) | 9.44 months (7.59-12.15) | 0.3831 |
| 3-month PFS (95% CI) | 87.53% (73.78-101.27) | 90.75% (82.96-98.55) | |
| 6-month PFS (95% CI) | 81.74% (65.59-97.88) | 75.99% (64.50-87.49) | |
| 12-month PFS (95% CI) | 62.18% (41.93-82.42) | 36.91% (23.66-50.15) | |
| 18-month PFS (95% CI) | 29.95% (10.84-49.07) | 19.83% (8.80-30.86) | |
| Median OS (95% CI) | 42.81 months (28.40-54.32) | 32.92 months (24.77-40.62) | 0.1654 |
| 12-month OS (95% CI) | 89.38% (76.59-102.18) | 87.94% (79.14-96.75) | |
| 24-month OS (95% CI) | 73.50% (54.87-92.13) | 64.27% (50.69-77.86) | |
| 36-month OS (95% CI) | 63.45% (39.55-87.35) | 39.89% (23.75-56.04) | |
| TK | p-value(Log rank test) | ||
| ≤ 8 U/l (n = 39) | > 8 U/l (n = 46) | ||
| Median PFS (95% CI) | 10.56 months (7.89-17.50) | 9.95 months (7.35-12.67) | 0.1209 |
| 3-month PFS (95% CI) | 87.08% (76.55-97.60) | 91.42% (83.33-99.51) | |
| 6-month PFS (95% CI) | 76.84% (63.60-90.08) | 75.17% (62.69-87.65) | |
| 12-month PFS (95% CI) | 47.06% (30.90-63.21) | 40.61% (26.42-54.79) | |
| 18-month PFS (95% CI) | 31.69% (16.37-47.00) | 17.35% (6.41-28.30) | |
| Median OS (95% CI) | 41.76 months (28.30-52.51) | 32.91 months (19.58-39.86) | 0.2161 |
| 12-month OS (95% CI) | 86.00% (74.85-97.15) | 88.28% (78.99-97.57) | |
| 24-month OS (95% CI) | 73.62% (59.06-88.18) | 59.28% (44.49-74.07) | |
| 36-month OS (95% CI) | 56.62% (37.60-75.64) | 42.41% (25.35-59.48) | |